Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 17/20 | 0.64 |
| ▸ | ITGAV | P06756 | 17/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5878133 | 1.00 | ITGB3 (0.64) | ITGB3ITGAVALOX15SMN1; SMN2GLA | |
| SCHEMBL5878634 | 0.89 | ITGB3 (0.66) | ITGB3ITGAV | |
| SCHEMBL7679035 | 0.89 | ITGB3 (0.66) | ITGB3ITGAV | |
| SCHEMBL5878631 | 0.89 | ITGB3 (0.66) | ITGB3ITGAV | |
| SCHEMBL5878332 | 0.88 | ITGB3 (0.69) | ITGB3ITGAVALOX15SMN1; SMN2 | |
| SCHEMBL5878276 | 0.86 | ITGB3 (0.64) | ITGB3ITGAVSMN1; SMN2 | |
| SCHEMBL5878092 | 0.85 | ITGB3 (0.65) | ITGB3ITGAV | |
| SCHEMBL5878086 | 0.85 | ITGB3 (0.65) | ITGB3ITGAV | |
| SCHEMBL5878731 | 0.84 | ITGB3 (0.89) | ITGB3ITGAV | |
| SCHEMBL5878735 | 0.84 | ITGB3 (0.89) | ITGB3ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7094911-B2 | Biphenyl and biphenyl-analogous compounds as integrin antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2006-08-22 | — | — | US | disclosed |
| EP-1140809-B1 | NEW BIPHENYL AND BIPHENYL-ANALOGOUS COMPOUNDS AS INTEGRIN ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2005-08-31 | — | — | EP | disclosed |
| US-20040030132-A1 | New biphenyl and biphenyl-analogous compounds as integrin antagonists | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-02-12 | — | — | US | disclosed |
| US-6677360-B2 | TREATMENT AND PROPHYLAXIS OF CANCER, ARTERIOSCLEROSIS, RESTENOSIS, OSTEOPOROSIS AND EYE DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2004-01-13 | — | — | US | disclosed |
| US-6420396-B1 | TREATMENT OF CANCER, ARTERIOSCLEROSIS, RESTENOSIS, OSTEOLYTIC DISORDERS, OPHTHALMIC DISORDERS, AND THEIR USE AS INTEGRIN ANTAGONISTS. INHIBITING ANGIOGENESIS | BEIERSDORF AG (DE) | 2002-07-16 | — | — | US | disclosed |
| US-20020016461-A1 | Biphenyl and biphenyl-analogous compounds as integrin antagonists | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2002-02-07 | — | — | US | disclosed |
| EP-1140809-A1 | NEW BIPHENYL AND BIPHENYL-ANALOGOUS COMPOUNDS AS INTEGRIN ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035864-A1 | NEW BIPHENYL AND BIPHENYL-ANALOGOUS COMPOUNDS AS INTEGRIN ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040030132-A1 | New biphenyl and biphenyl-analogous compounds as integrin antagonists | ITGB2, ITGB1, ITGB3 | ITGB3 3/4885ITGAV 13/4885ALOX15 1944/4885 |
| US-20020016461-A1 | Biphenyl and biphenyl-analogous compounds as integrin antagonists | ITGB1, ITGB2, ITGB3 | ITGB3 3/4885ITGAV 13/4885ALOX15 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.